12-94308911-GT-G
Position:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_016122.3(CEP83):βc.2007delβ(p.Glu669AspfsTer14) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000872 in 1,606,224 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (β β ).
Frequency
Genomes: π 0.000066 ( 0 hom., cov: 32)
Exomes π: 0.0000028 ( 0 hom. )
Consequence
CEP83
NM_016122.3 frameshift
NM_016122.3 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 0.158
Genes affected
CEP83 (HGNC:17966): (centrosomal protein 83) The protein encoded by this gene is a centriolar protein involved in primary cilium assembly. Defects in this gene have been associated with infantile nephronophthisis and intellectual disability. [provided by RefSeq, Oct 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most exon, not predicted to undergo nonsense mediated mRNA decay. Fraction of 0.047 CDS is truncated, and there are 1 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 12-94308911-GT-G is Pathogenic according to our data. Variant chr12-94308911-GT-G is described in ClinVar as [Pathogenic]. Clinvar id is 1070747.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr12-94308911-GT-G is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
CEP83 | NM_016122.3 | c.2007del | p.Glu669AspfsTer14 | frameshift_variant | 17/17 | ENST00000397809.10 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
CEP83 | ENST00000397809.10 | c.2007del | p.Glu669AspfsTer14 | frameshift_variant | 17/17 | 1 | NM_016122.3 | P1 | |
CEP83 | ENST00000339839.9 | c.2007del | p.Glu669AspfsTer14 | frameshift_variant | 16/16 | 1 | P1 | ||
CEP83 | ENST00000552632.5 | c.399del | p.Glu133AspfsTer14 | frameshift_variant | 4/5 | 3 | |||
CEP83 | ENST00000546783.1 | n.461del | non_coding_transcript_exon_variant | 3/3 | 3 |
Frequencies
GnomAD3 genomes AF: 0.0000657 AC: 10AN: 152128Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
10
AN:
152128
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.00000275 AC: 4AN: 1454096Hom.: 0 Cov.: 27 AF XY: 0.00000414 AC XY: 3AN XY: 723920
GnomAD4 exome
AF:
AC:
4
AN:
1454096
Hom.:
Cov.:
27
AF XY:
AC XY:
3
AN XY:
723920
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000657 AC: 10AN: 152128Hom.: 0 Cov.: 32 AF XY: 0.0000673 AC XY: 5AN XY: 74298
GnomAD4 genome
AF:
AC:
10
AN:
152128
Hom.:
Cov.:
32
AF XY:
AC XY:
5
AN XY:
74298
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Sep 04, 2023 | Frameshift variant predicted to result in protein truncation as the last 33 amino acids are replaced with 13 different amino acids, although loss-of-function variants have not been reported downstream of this position in the protein; Published functional studies demonstrate a damaging effect on centrosome localization and interactions with its binding partner, CEP164 (Failler et al., 2014); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 24882706, 30655312) - |
Nephronophthisis 18 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Apr 06, 2023 | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the CEP83 protein in which other variant(s) (p.Gln692del) have been observed in individuals with CEP83-related conditions (PMID: 24882706). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. Experimental studies have shown that this premature translational stop signal affects CEP83 function (PMID: 24882706). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. ClinVar contains an entry for this variant (Variation ID: 1070747). This premature translational stop signal has been observed in individuals with nephronophthisis (PMID: 24882706, 30655312). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Glu669Aspfs*14) in the CEP83 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 33 amino acid(s) of the CEP83 protein. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at